On Dec 12, 2024, the US Food and Drug Administration (FDA) approved crinecerfont for adults and paediatric patients with classic congenital adrenal hyperplasia.1 ...

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) and Takeda Pharmaceutical Co Ltd (NYSE:TAK) released topline results for the ...

Eisai plans to lay off 121 employees in the U.S. A former deputy director of China's drug agency is under investigation by anti-corruption authorities. | Eisai plans to lay off 121 employees in the U.

Treatment-resistant depression complicates care, defying standard treatments, but new therapies are on the horizon, offering hope for more effective treatment options.

We recently published a list of 15 Best Fast Growth Stocks To Buy Right Now. In this article, we are going to take a look at ...

Intra-Cellular Therapies' CAPLYTA is making waves in the antipsychotic market, gaining traction as a novel treatment for schizophrenia and bipolar de ...

Neurocrine Biosciences ... In January, the firm announced an amended agreement with Takeda to develop and commercialize osavampator. The company will now have exclusive rights to develop and ...

Neurocrine Biosciences Inc. (NASDAQ:NBIX), a biopharmaceutical company specializing in neurological and endocrine-related disorders, finds itself at a critical juncture as it navigates a shifting ...

We recently published a list of 10 Top Insider Stock Buys And Sells In January. In this article, we are going to take a look at where Neurocrine (NASDAQ:NBIX) stands against other top insider stock ...